Citations 1
Phase I/II study of letrozole and sorafenib as first-line therapy of hormone-receptor positive (HR+) metastatic breast cancer (MBC).
Tan, Antoinette R. , Wong, Serena, Warren, Robert, EngâWong, Jennifer , Liu, Minetta C. , Zelnak, Amelia, Shih, Weichung, Ganesan, Shridar , Grana, Generosa , Toppmeyer, Deborah , Lin, Yong , Isaacs, Claudine
Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 531-531
